Berjame, Anecito S.
HRN: 08-68-89 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/02/2024
AZITHROMYCIN 500MG TABLET (TAB)
05/02/2024
05/06/2024
ORAL
500mg
OD
Transglottic Squamous Cell CA Stage IV C; S/P Tracheosomy
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft TissueEye, Ear, Nose, Throat, & Mouth Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes